Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.73 |
| ▸ | NPC1 | O15118 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | ATM | Q13315 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12031703 | 0.89 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL12031680 | 0.86 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL8909412 | 0.84 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL7690719 | 0.84 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL12031737 | 0.83 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL7962367 | 0.83 | HPGD (0.55) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL1651601 | 0.81 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL5838513 | 0.81 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL12031697 | 0.81 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL9423226 | 0.80 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026358-B2 | Coupling (2-iodo-3-methyl-5-pyrrolyl)(2-iodo-4-methyl-5-pyrrolyl)methane or derivative with bis(2-formyl-3-methyl-4-(2-alkoxycarbonylethyl)4-pyrrolyl)methane in an acidic medium with optiona hydrolsis or saponification; preparing heme, hemin or hematin | SANOFI PASTEUR S.A. (FR) | 2011-09-27 | — | — | US | disclosed |
| US-20080242857-A1 | Coupling (2-iodo-3-methyl-5-pyrrolyl)(2-iodo-4-methyl-5-pyrrolyl)methane or derivative with bis(2-formyl-3-methyl-4-(2-alkoxycarbonylethyl)4-pyrrolyl)methane in an acidic medium with optiona hydrolsis or saponification; preparing heme, hemin or hematin | SANOFI PASTEUR SA (FR) | 2008-10-02 | — | — | US | disclosed |
| US-6201129-B1 | ANTICARCINOGENIC AGENTS | UNIV. COLLEGE CARDIFF CONSULTANTS (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-0807113-A1 | TRICYCLIC DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | University College Cardiff Consultants Limited (GB) | 1997-11-19 | — | — | EP | disclosed |
| US-5679694-A | LOW TOXICITY AGAINST NORMAL CELL LINES | THE WELLCOME FOUNDATION LTD. (GB) | 1997-10-21 | — | — | US | disclosed |
| WO-1995021171-A1 | TRICYCLIC DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 1995-08-10 | — | — | WO | disclosed |
| EP-0651750-A1 | TETRACYCLIC COMPOUNDS PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOUR AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002483-A1 | TETRACYCLIC COMPOUNDS PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOUR AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242857-A1 | Coupling (2-iodo-3-methyl-5-pyrrolyl)(2-iodo-4-methyl-5-pyrrolyl)methane or derivative with bis(2-formyl-3-methyl-4-(2-alkoxycarbonylethyl)4-pyrrolyl)methane in an acidic medium with optiona hydrolsis or saponification; preparing heme, hemin or hematin | MB, CYC1, MDN1 | RAB9A 3893/4885NPC1 4116/4885SMN1; SMN2 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.